Follow-up Trial to Evaluate Long-term Safety and Efficacy of Brivaracetam in Subjects Suffering From Epilepsy

PHASE3CompletedINTERVENTIONAL
Enrollment

853

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

May 31, 2019

Study Completion Date

May 31, 2019

Conditions
Epilepsy
Interventions
DRUG

Brivaracetam (ucb 34714)

10 mg and 25 mg tablets. Flexible dosing up to 200 mg/day, twice daily. For each subject, the study will last from study entry until either regulatory approval of brivaracetam has been granted by any Health Authority in an indication of adjunctive treatment of partial onset seizures; or until the Sponsor decides to close the study; until a managed access program, named patient program, compassionate use program, or similar type of access program is established as allowed per country-specific requirements in addition to legal and regulatory guidelines, or until the investigational product development is stopped by the Sponsor.

Trial Locations (153)

22908

931, Charlottesville

32610

933, Gainesville

94115

935, San Francisco

Unknown

509, Graz

507, Innsbruck

510, Linz

508, Vienna

501, Edegem

515, Montignies-sur-Sambre

506, Bruges

513, Ghent

974, La Louvière

505, Leuven

951, Vancouver

950, Montreal

952, Québec

545, Beroun

543, Brno

544, Brno

546, České Budějovice

519, Ostrava Trebovice

517, Prague

541, Prague

542, Prague

518, Zlín

900, Helsinki

581, Kuopio

526, Oulu

582, Oulu

527, Seinäjoki

583, Tampere

811, Tampere

633, Lyon

632, Angers

628, Béthune

630, Dijon

624, Lille

625, Marseille

623, Montpellier

635, Nancy

626, Paris

920, Paris

622, Rennes

528, Roanne

823, Saint-Pierre-des-Corps

627, Strasbourg

634, Toulouse

532, Bad Berka

705, Berlin

708, Berlin

536, Bernau

707, Bielefeld

701, Bonn

709, Erlangen

703, Frankfurt

711, Freiburg im Breisgau

537, Göttingen

535, Jena

710, Kehl

531, Liegau-Augustusbad

533, Mainz

560, München

706, München

704, Ulm

649, Hong Kong

650, Shatin

547, Budapest

538, Debrecen

539, Pécs

970, Tel Aviv

830, Bologna

553, Foggia

831, Messina

563, Milan

832, Milan

833, Napoli

554, Pavia

550, Perugia

552, Roma

555, Roma

559, Roma

973, Siena

566, Breda

821, Heemstede

822, Heeze

567, The Hague

571, Fredrikstad

568, Oslo

569, Sandvika

570, Trondheim

575, Bialystok

741, Gdansk

978, Grodzisk Mazowiecki

748, Katowice

976, Katowice

574, Kielce

975, Krakow

744, Lodz

747, Lodz

742, Lublin

977, Poznan

746, Szczecin

573, Warsaw

576, Warsaw

577, Warsaw

743, Warsaw

745, Warsaw

591, Kazan'

578, Moscow

579, Moscow

584, Moscow

586, Moscow

588, Moscow

589, Saint Petersburg

943, Samara

587, Yaroslavl

961, Belgrade

962, Belgrade

657, Singapore

648, George

655, Gwangju

652, Seoul

653, Seoul

654, Seoul

656, Seoul

599, Alcorcón

593, Barcelona

596, Donostia / San Sebastian

594, Madrid

783, Madrid

786, Madrid

595, Vigo

597, Zaragoza

850, Gothenburg

601, Stockholm

604, Umeå

605, Biel

607, Sankt Gallen

606, Tschugg

608, Zurich

671, Taichung

672, Taichung

669, Tainan City

660, Taoyuan District

861, Manouba

860, Tunis

638, Donetsk

637, Kharkiv

641, Kyiv

642, Kyiv

639, Lviv

643, Odesa

640, Uzhhorod

Sponsors

Lead Sponsor

All Listed Sponsors
lead

UCB Pharma

INDUSTRY